Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250851 | 1.00 | EPHX2 (0.55) | EPHX2HRH3KDM1AALDH1A1ALOX15 | |
| SCHEMBL5572377 | 0.81 | ALDH1A1 (0.56) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2385630 | 0.76 | ALDH1A1 (0.49) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2383819 | 0.76 | ALDH1A1 (0.67) | HRH3ALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL2384241 | 0.75 | ALDH1A1 (0.54) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2382793 | 0.74 | PANK3 (0.54) | P2RY12 | |
| SCHEMBL2385551 | 0.74 | TRPV1 (0.51) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2384061 | 0.74 | GPR119 (0.63) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2383147 | 0.74 | MEN1 (0.45) | ALDH1A1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL2382772 | 0.74 | TRPV1 (0.49) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | EPHX2 872/4885HRH3 2015/4885KDM1A 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.